SG11202100092QA - USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS - Google Patents

USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS

Info

Publication number
SG11202100092QA
SG11202100092QA SG11202100092QA SG11202100092QA SG11202100092QA SG 11202100092Q A SG11202100092Q A SG 11202100092QA SG 11202100092Q A SG11202100092Q A SG 11202100092QA SG 11202100092Q A SG11202100092Q A SG 11202100092QA SG 11202100092Q A SG11202100092Q A SG 11202100092QA
Authority
SG
Singapore
Prior art keywords
mitochonrial
disorders
treatment
sgc stimulators
sgc
Prior art date
Application number
SG11202100092QA
Other languages
English (en)
Inventor
John Hadcock
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of SG11202100092QA publication Critical patent/SG11202100092QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202100092QA 2018-07-11 2019-07-11 USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS SG11202100092QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696582P 2018-07-11 2018-07-11
US201862697671P 2018-07-13 2018-07-13
PCT/US2019/041437 WO2020014504A1 (fr) 2018-07-11 2019-07-11 Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales

Publications (1)

Publication Number Publication Date
SG11202100092QA true SG11202100092QA (en) 2021-02-25

Family

ID=67480342

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100092QA SG11202100092QA (en) 2018-07-11 2019-07-11 USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS

Country Status (15)

Country Link
US (1) US20210177846A1 (fr)
EP (1) EP3820476A1 (fr)
JP (1) JP2021530491A (fr)
KR (1) KR20210031931A (fr)
CN (1) CN112384220A (fr)
AU (1) AU2019301683A1 (fr)
BR (1) BR112021000358A2 (fr)
CA (1) CA3103676A1 (fr)
CL (1) CL2021000030A1 (fr)
IL (1) IL279636A (fr)
MA (1) MA53127A (fr)
MX (1) MX2021000363A (fr)
PH (1) PH12021550047A1 (fr)
SG (1) SG11202100092QA (fr)
WO (1) WO2020014504A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169671A1 (fr) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations de carbamate de methyle {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2021167458A1 (fr) * 2020-02-21 2021-08-26 Universiteit Maastricht Utilisation d'un stimulateur de guanylate cyclase soluble (sgc) ou d'une combinaison d'un stimulateur de sgc et d'un activateur de sgc dans des conditions dans lesquelles le groupe hème de sgc est oxydé ou sgc est déficient en hème
WO2022081610A1 (fr) * 2020-10-13 2022-04-21 Cyclerion Therapeutics, Inc. Traitement d'une déficience cognitive au moyen d'un stimulateur de sgc pénétrant dans le système nerveux central
EP4154888A1 (fr) 2021-09-24 2023-03-29 Charité - Universitätsmedizin Berlin Inhibiteur pde5 destiné à être utilisés dans le traitement d'affections médicales associées à un déficit en complexe v mitochondrial
WO2023239908A1 (fr) 2022-06-09 2023-12-14 Tisento Therapeutics Inc. Traitement de maladies mitochondriales avec le stimulateur de la sgc pénétrant dans le snc tel que le zagociguat
WO2024086182A1 (fr) 2022-10-18 2024-04-25 Tisento Therapeutics Inc. Traitement de maladies mitochondriales avec stimulateurs de sgc

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
EE9900151A (et) 1996-10-14 1999-12-15 Bayer Aktiengesellschaft Heterotsüklüülmetüül-asendatud pürasooliderivaadid
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19962926A1 (de) 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
DE10054278A1 (de) 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10242941A1 (de) 2002-09-16 2004-03-18 Bayer Ag Substituiertes Pyrazolderivat
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
US20070148136A1 (en) * 2003-09-26 2007-06-28 Whitlock David R Methods of using ammonia oxidizing bacteria
WO2005084660A1 (fr) * 2004-03-05 2005-09-15 Morishige, Fumie Prévention de et mesure contre la maladie mitochondriale
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006021733A1 (de) 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102006054757A1 (de) 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
EP2150616A4 (fr) 2007-05-10 2011-07-27 Univ Arizona Expression régulée d'antigène et/ou atténuation régulée pour accroître l'immunogénicité et/ou la sécurité de vaccins
WO2009032249A1 (fr) 2007-09-06 2009-03-12 Merck & Co., Inc. Activateurs de la guanylate cyclase soluble
US8397065B2 (en) 2007-10-17 2013-03-12 Telcordia Technologies, Inc. Secure content based routing in mobile ad hoc networks
AU2009206635A1 (en) 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
MX2011008952A (es) 2009-02-26 2011-09-27 Merck Sharp & Dohme Activadores de guanilato ciclasa solubles.
PE20121742A1 (es) 2009-11-27 2012-12-13 Adverio Pharma Gmbh PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
RU2012129671A (ru) 2009-12-14 2014-01-27 Байер Интеллектуэль Проперти Гмбх НОВЫЕ СОЛЬВАТЫ МЕТИЛ (4, 6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1Н-ПИРАЗОЛО[3, 4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ)КАРБАМАТА
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2011119518A1 (fr) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Activateurs de guanylate cyclase solubles
ME02207B (me) 2010-05-26 2016-02-20 Adverio Pharma Gmbh UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
NZ603884A (en) 2010-05-27 2014-06-27 Merck Sharp & Dohme Soluble guanylate cyclase activators
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
KR20130132392A (ko) 2010-07-09 2013-12-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 가용성 구아닐레이트 시클라제의 자극제로서의 고리-융합된 4-아미노피리미딘 및 그의 용도
DE102010031667A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung
DE102010031665A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
CA2834901A1 (fr) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Imidazopyridazines substituees et imidazopyridazines, et leur utilisation
DE102011075398A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
CN103608347B (zh) 2011-05-30 2016-04-27 安斯泰来制药株式会社 咪唑并吡啶化合物
ES2648810T3 (es) 2011-07-06 2018-01-08 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de la guanilato ciclasa soluble
AU2012300844B2 (en) 2011-09-02 2017-03-30 Bayer Intellectual Property Gmbh Substituted annellated pyrimidine and the use thereof
CA3040720C (fr) 2011-11-25 2021-06-15 Adverio Pharma Gmbh Procede de production de 5-fluoro-1h-pyrazolopyridines substituees
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
CA2861804C (fr) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. Pyrazoles 2-benzyle, 3-(pyrimidin-2-yle)-substitues utiles comme stimulateurs de scg
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
ES2644781T3 (es) 2012-03-06 2017-11-30 Bayer Intellectual Property Gmbh Azabiciclos sustituidos y su uso
WO2014047111A1 (fr) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
CA2885645A1 (fr) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
BR112015012571B1 (pt) 2012-11-30 2022-05-24 Astellas Pharma Inc Compostos de imidazopiridina e usos terapêuticos dos mesmos
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
WO2014131760A1 (fr) 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
EP2961754B1 (fr) 2013-03-01 2016-11-16 Bayer Pharma Aktiengesellschaft Pyrazolopyridines à substitution benzyle et leur utilisation
CN109369635B (zh) 2013-03-15 2023-06-30 赛克里翁治疗有限公司 化合物或其药学上可接受的盐及其应用和药物组合物
CA2914100A1 (fr) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines a substitution 3-aryle et leur utilisation
CA2920565A1 (fr) 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Pyrazolo[1,5-a]pyridine-3-carboxamides substitues et leur utilisation
EP3062780A1 (fr) * 2013-11-01 2016-09-07 Bergen Teknologioverføring AS Activateurs ou stimulateurs de guanylate cyclase soluble destinés à être utilisés pour traiter un syndrome de fatigue chronique
WO2015082411A1 (fr) 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-3-carboxamides aryl et hétéroaryl substitués et leur utilisation
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3079700B1 (fr) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015124544A1 (fr) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines
EP3119777A1 (fr) 2014-03-21 2017-01-25 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-carboxamides cyano-substitués et leur utilisation
JP2017508811A (ja) 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト 置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用
CA2944614A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques a disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150364A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides benzotriazinonebutyriques substitués et leur utilisation
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015150366A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Dérivés d'éthers phénoliques à substitutions cycliques et leur utilisation
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EP3194386A2 (fr) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
CA2961531A1 (fr) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN108463224A (zh) * 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
US20170182088A1 (en) * 2015-12-28 2017-06-29 Geno Llc Method and apparatus for administering nitric oxide with supplemental drugs
JP7098214B2 (ja) * 2016-02-01 2022-07-11 サイクレリオン・セラピューティクス，インコーポレーテッド 非アルコール性脂肪性肝炎（ＮＡＳＨ）の処置のためのｓＧＣ刺激物質の使用
CA3029374A1 (fr) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Promedicaments a base de phosphore de stimulateurs de sgc
BR112019004468A2 (pt) * 2016-09-02 2019-05-28 Ironwood Pharmaceuticals Inc estimulantes de sgc
EP3538096B1 (fr) 2016-11-08 2024-02-28 Tisento Therapeutics Inc. Traitement de maladies du snc au moyen de stimulateurs de gcs
CN110267949A (zh) * 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
US11897887B2 (en) 2017-12-19 2024-02-13 Tisento Therapeutics Inc. sGC stimulators
MX2023004857A (es) * 2018-03-07 2023-11-24 Cyclerion Therapeutics Inc Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc).

Also Published As

Publication number Publication date
MA53127A (fr) 2021-05-19
CA3103676A1 (fr) 2020-01-16
CL2021000030A1 (es) 2021-05-28
CN112384220A (zh) 2021-02-19
US20210177846A1 (en) 2021-06-17
MX2021000363A (es) 2021-04-29
KR20210031931A (ko) 2021-03-23
BR112021000358A2 (pt) 2021-04-06
WO2020014504A1 (fr) 2020-01-16
IL279636A (en) 2021-03-01
PH12021550047A1 (en) 2021-11-22
EP3820476A1 (fr) 2021-05-19
JP2021530491A (ja) 2021-11-11
AU2019301683A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL271085A (en) Bacteria to treat disorders
IL276032A (en) Compounds for the treatment of kinase-dependent disorders
IL276398A (en) Combined treatment for mastocytosis
SG11202100092QA (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
IL279260A (en) KDM1A inhibitors for the treatment of diseases
ZA202007055B (en) Compositions for the treatment of skin conditions
ZA202006610B (en) Compositions for the treatment of skin conditions
IL267818A (en) Methods for treating neurological disorders
IL276482A (en) Compounds for pain management
IL259639A (en) Use of sgc stimulators to treat gastrointestinal sphincter dysfunction
IL287280A (en) Compounds and methods for the treatment of ocular disorders
IL276028A (en) Compounds for the treatment of kinase-dependent disorders
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
EP3897641C0 (fr) Traitement de troubles du mouvement
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL288234A (en) Compounds for the treatment of neuromuscular disorders
SG11202007642RA (en) Treatment of disorders with tasimelteon
PT3724173T (pt) Compostos para o tratamento de distúrbios neuromusculares
IL276697A (en) 3 Beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders
GB201808821D0 (en) Treatment of metabolic disorders